

ASX RELEASE

Volpara Quarterly Results and Investor Conference call

Wellington, NZ, 22 October 2018: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, is pleased to advise it will release its Appendix 4C – Quarterly Cash Flow Statement for the period ended 30 September 2018 (Q2 FY19) on 29 October 2018.

Investors are invited to join a conference call hosted by CEO Dr Ralph Highnam, CFO Craig Hadfield and CCO Mark Koeniguer at 9am AEDT (11am NZDT) 29 October 2018.

To pre-register, please follow this link:

<https://services.choruscall.com.au/diamondpass/volpara-453122-invite.html>

You will receive a calendar notification with dial-in details and a PIN for fast-track access to the call.

ENDS.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@we-buchan.com
t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, provides role specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 36 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$40 million, including A\$20 million in April and May 2018. VHT is based in Wellington, New Zealand.

For more information, visit www.volparasolutions.com